eligible patient – Page 8 – Communicable Diseases Research

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

중환자 COVID-19 환자에서 회복기 혈장 사용의 효능

Article

Published on 2021-03-112022-09-10
Journal: Medicina [Category] SARS, 치료제,

Liuzijue is a promising exercise option for rehabilitating discharged COVID-19 patients

Clinical Trial

Published on 2021-02-122022-10-05
Journal: Medicine [Category] 임상,

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

Observational Study

Published on 2021-02-012022-10-05
Journal: The Journal of Infection [Category] Fulltext, MERS, 임상,

[키워드] 95% confidence interval Admission baseline C-reactive protein (CRP Characteristics clinical suspicion Cohort Computed tomography consecutive patient COVID-19 COVID-19 infection CRP level D-dimer D-dimer level determine elevated eligible patient exclusion criteria hazard heart rate hospital Hospitalization Hospitalized hospitalized COVID-19 patients incidence inclusion criteria independent predictor Inflammation Multivariate analysis oxygen saturation Patient patients hospitalized performed pharmacological Predictive prospective observational study pulmonary pulmonary angiography Pulmonary embolism Randomly Ratio risk risk factor Risk factors selected Spain Thromboprophylaxis thrombosis thrombotic Valencia variable
[DOI] 10.1016/j.jinf.2021.01.003 PMC 바로가기 [Article Type] Observational Study

The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial

Research article

Published on 2021-02-012022-10-05
Journal: European Journal of Integrative Medicine [Category] 임상,

[키워드] 28-day mortality affected affecting anti-inflammatory effect C-reactive protein (CRP China clinical symptom control group controls country COVID-19 Critically ill Cytokine storm double-blinded dropped eligible patient Hospitalization ICU IL-6 IL-8 immunomodulation immunoregulation Inflammatory cytokine injection investigated lymphocyte mechanical ventilation medication Mortality Necrosis not significantly different Patient Prevent pro-inflammatory cytokines proportion Randomized Randomized controlled trial recruited reduce Result secretion Sepsis Septic shock serious adverse reaction severe COVID-19 severe COVID-19 patient Severe patient severe pneumonia significant difference significantly suppress suppressed the cytokine storm TNF Treatment treatment group Trial xuebijing injection
[DOI] 10.1016/j.eujim.2021.101305 [Article Type] Research article

Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019

항문 면봉에서 검출 가능한 SARS-COV-2 RNA와 코로나바이러스 질환 환자의 질병 중증도 사이의 연관성 2019

Article

Published on 2021-02-012022-09-11
Journal: Journal of medical virology [Category] SARS, 치료기술, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adjusted hazard ratio Anal anal swab anal swabs analyzed association C-reactive protein Clinical significance collected coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cumulative cumulative incidence detectable digestive tract disease severity early stage eligible patient excluded feces females Follow-up Guangzhou High-flow nasal cannula Hospitalized Hypoxemia ICU ICU admission incidence intensive care intensive care unit intestine intestines laboratory data laboratory-confirmed lymphocytopenia measure median nasal nasal cannula oxygen oxygen support Patient patients respiratory RNA SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 RNA detection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease Swab test results the disease the patient Throat throat swab throat swabs Viral Viral load Viral RNA
[DOI] 10.1002/jmv.26307 PMC 바로가기 [Article Type] Article

Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

중증 코로나19 환자에서 이카티반트 및 C1 에스테라제/칼리크레인 억제제의 효능 및 안전성 평가: 3군 무작위 대조 시험 연구 프로토콜

Study Protocol

Published on 2021-01-202022-09-10
Journal: Trials [Category] 비임상, 임상,

[키워드] accumulation ACE inhibitor ACE inhibitors ACE2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animal models anti-inflammatory agents antibiotic antithrombotic therapy assigned binding bradykinin breath C1 esterase inhibitor cause Cell clinical clinical trial clinical trials cough COVID-19 Degradation dependent on driving Efficacy and safety eligible patient expressed Icatibant inactivation include Inflammatory inhibitor intravenously invasive ventilation leads lipopolysaccharide LPS lung lung inflammatory response Lungs mechanism mortality rates Non-invasive number Open-label oxygen parallel-group Pneumonia Pneumonitis Prophylactic Protein randomized clinical trial Randomized controlled trial Randomly receive reduce registry renal replacement therapy replacement therapy Respiratory failure SARS-CoV-2 severe COVID-19 patient severe COVID-19 patients Severity of disease Side effect single-center standard care Study protocol subcutaneously supplemental oxygen the cells Universal vasopressor support viral-induced virus
[DOI] 10.1186/s13063-021-05027-9 PMC 바로가기 [Article Type] Study Protocol

Evaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial

중등도 또는 중증 COVID-19 환자에 대한 표준 치료와 함께 흡입 황산마그네슘의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-182022-09-10
Journal: Trials [Category] 임상,

[키워드] 1:1 acute severe asthma adjuvant therapy Administered Affect airway smooth muscle alveolar Anti-inflammatory anticipated Arm ARMS arterial blood arterial blood oxygen saturation arterial oxygen saturation arteriole Artery Asthma attack basic Blinding block Block randomisation blocks blood oxygen Blood oxygen saturation bradyarrhythmia calcium calcium antagonist cardiovascular disease cardiovascular diseases Chest computed tomography Chest CT chest CT scan clinical clinical impact clinical manifestation clinical manifestations Clinical studies clinical study clinical trials Combination Computed tomography Computer software Confirmed congestive heart failure Control Controlled trial cough COVID-19 criteria defined diagnosis of SARS-CoV-2 dissemination Dyspnoea Effect Effects Efficacy and safety eight element eligible patient Eligible patients excluded FIVE functional heart block hospital Hospital stay Hospitalized hospitalized patient hospitalized patients Hypoxemia hypoxia impairment IMPROVE improvement inclusion criteria induce Infection inhalation Inhaled Intervention intervention arm intravenous intravenously Length Lung injury lung involvement magnesium sulphate Mask moderate myocardial injury nasopharyngeal secretion National nebulized number objective Open-label outcome oxygen oxygen saturation Parallel Arm parenchyma participant Patient patients with moderate PCR performed polymerase chain polymerase chain reaction protocol pulmonary artery pulmonary involvement randomisation randomised randomised controlled trial randomization Randomly randomly divided RCT receive reduce Registered registration number registry respiratory respiratory airway respiratory airways Respiratory function respiratory tract respiratory tract symptoms Sample size SARS-COV-2 infection saturation severe COVID-19 Shortness of breath shown smooth muscle relaxant standard treatment status Study protocol supplementary material Symptom Tehran therapy Trial Trial registration Ventilation Version website with COVID-19 Yazd
[DOI] 10.1186/s13063-021-05032-y PMC 바로가기 [Article Type] Letter

Prognostic Factors for 30-Day Mortality in Critically Ill Patients With Coronavirus Disease 2019: An Observational Cohort Study

Observational Study

Published on 2021-01-012022-10-05
Journal: Critical Care Medicine [Category] 임상,

[키워드] 24 hour 30-Day mortality age association Blood body mass index Characteristics cohort study Concentration continuous variable coronavirus disease Cox proportional hazard Critical care Critically ill cubic splines death Deprivation died eligible eligible patient England Factor hemoglobin highest hospital identify Ill Immunocompromise Interaction Ireland Lactate less likelihood lowest main outcome measure male measurement mechanical ventilation median age Patient Platelet predict Prognostic factor Prognostic factors receiving respiratory rate Sedation serum Sex Significant Support Systolic blood pressure temperature urea variable variables
[DOI] 10.1097/CCM.0000000000004740 PMC 바로가기 [Article Type] Observational Study

[Hypoxia and inflammation are risk factors for acute myocardial injury in patients with coronavirus disease 2019]

[2019년 코로나바이러스 환자에서 저산소증과 염증은 급성 심근 손상의 위험 요소입니다]

Article

Published on 2020-12-282022-09-11
Journal: Beijing da xue xue bao. Yi xue ban = Journal of Pe [Category] MERS, SARS, 바이오마커,

[키워드] 95% CI acute myocardial injury Admission Betacoronavirus C-reactive protein cardiac troponin Cardiology Chinese clinical clinical information collected coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 cohort COVID-19 patient COVID-19 patients Critical case cTn defined disease eligible patient Eligible patients English enrolled European evaluated except for Factor ferritin High-sensitivity C-reactive protein hs-CRP IL-6 IL-6 level IL-8 independent risk factor independent risk factors Inflammation Inflammatory information Injury interleukin interleukin-2 interleukin-6 interleukin-8 Laboratory test Laboratory tests Logistic regression analyses Lower Myocardial Myocardial infarction myocardial injury Necrosis Older on admission oxygen oxygen saturation Oxygen therapy Pathogenesis Patient patients Percutaneous plasma positive correlation proportion receptor released respiratory rate Retrospective analysis risk factor Risk factors Society Spearman correlation test the patient TNF-α Tumor tumor necrosis tumor necrosis factor tumor necrosis factor α with COVID-19
[DOI] 10.19723/j.issn.1671-167X.2021.01.024 PMC 바로가기 [Article Type] Article

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

입원한 중증 COVID-19 환자를 위한 치료제로서의 정맥내 메틸프레드니솔론 펄스: 무작위 대조 임상 시험의 결과

Randomized Controlled Trial

Published on 2020-12-242022-08-13
Journal: The European Respiratory Journal [Category] 임상,

[키워드] 1:1 95% CI administration Analysis attending physician Block randomisation Clinical improvement clinical trial conducted Controlled clinical trial Corticosteroid Corticosteroids COVID-19 COVID-19 patient COVID-19 patients death demonstrated eligible patient hazard ratio hospitalised hospitalised patient Immunosuppressive treatment Inflammation Inflammatory marker inflammatory markers initiation of treatment intention-to-treat Intravenous injection Iran ITT log-rank test Methylprednisolone methylprednisolone group mortality rate oxygen oxygen saturation Patient pulmonary involvement pulse randomisation randomised controlled Randomly receive reduce respiratory Respiratory system Result safety analysis severe adverse event severe adverse events severe COVID-19 severe COVID-19 patient significantly increased significantly lower single-blind standard care standard care group suggested survival survival time therapeutic therapeutic agent Treatment Two patient two patients was done were excluded
[DOI] 10.1183/13993003.02808-2020 PMC 바로가기 [Article Type] Randomized Controlled Trial